Overview

Induction Chemo-Nivo in Unresectable Stage III NSCLC

Status:
Recruiting
Trial end date:
2027-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the response rate, safety, and effectiveness of a combination therapy in patients with lung cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Ralph G Zinner
Collaborator:
Bristol-Myers Squibb
Treatments:
Nivolumab